Title: Development and evaluation of a Novel RT‐PCR system for reliable and rapid SARS‐CoV ‐2 screening of blood donations

Abstract

Abstract Background The ongoing outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has caused great global concerns. In contrast to SARS, some SARS‐CoV‐2–infected people can be asymptomatic or have only mild nonspecific symptoms. Furthermore, there is evidence that SARS‐CoV‐2 may be infectious during an asymptomatic incubation period. With the discovery that SARS‐CoV‐2 can be detected in plasma or serum, blood safety is worthy of consideration. Study Design and Methods We developed a nucleic acid test (NAT) screening system for SARS‐CoV‐2 targeting nucleocapsid protein (N) and open reading frame 1ab (ORF 1ab) gene that could screen 5076 samples every 24 hours. The 2019 novel coronavirus RNA standard was used to evaluate linearity of standard curves. Diagnostic sensitivity and reproducibility were evaluated using artificial SARS‐CoV‐2. Specificity was evaluated with 61 other respiratory pathogens. Diagnostic performance was evaluated by testing two sputum and nine oropharyngeal swab specimens. The reverse transcription polymerase chain reaction (RT‐PCR) assay was used to screen SARS‐CoV‐2 RNA in blood donor specimens collected during the outbreak of SARS‐CoV‐2 in Chengdu. Results Limits of detection of the SARS‐CoV‐2 RT‐PCR assay for N and ORF 1ab gene were 12.5 and 27.58 copies/mL, respectively. Intra‐assay and interassay for the SARS‐CoV‐2 RT‐PCR assay basedmore » on cycle threshold were acceptably low. No cross‐reactivity was observed with other respiratory virus and bacterial isolates. The overall agreement value between the SARS‐CoV‐2 RT‐PCR assay and clinical diagnostic results was 100%. A total of 16 287 blood specimens collected from blood donors during SARS‐CoV‐2 surveillance were tested negative. Conclusions A high‐throughput NAT screening system was developed for SARS‐CoV‐2 screening of blood donations during the outbreak of SARS‐CoV‐2.« less

Authors:

Li, Meng ^[1]; Zhao, Yuwei ^[1]; Li, Ying ^[1]; Chen, Xue ^[1]; Luo, Dongxia ^[2]; Luo, Mei ^[3]; Hou, Jue ^[1]; Liu, Juan ^[4]; Liu, Humin ^[1]; Wang, Huan ^[1]; Dong, Yufang ^[1]; Zhang, Lanjiang ^[1]; Ji, Maosheng ^[1]; Zhao, Xin ^[1]; Wei, Caibing ^[1]; Li, Wen ^[1]; Gao, Jialiang ^[1]; Shan, Hua  ^[5];

• Search DOE PAGES for author "Shan, Hua"
• Search DOE PAGES for ORCID "0000-0003-3764-1787"

Fu, Xuemei  ^[1]

• Search DOE PAGES for author "Fu, Xuemei"
• Search DOE PAGES for ORCID "0000-0003-3371-6171"

---

+ Show Author Affiliations

1. Blood Research Laboratory Chengdu Blood Center Chengdu China
2. Teaching &, Research Department Public Health and Clinical Center of Chengdu Chengdu China
3. Infectious Disease Research Laboratory Public Health and Clinical Center of Chengdu Chengdu China
4. Productresearch &, Development Department Sansure Biotechnology Company Changsha China
5. Stanford University School of Medicine Stanford California USA

Publication Date:

Thu Sep 10 00:00:00 EDT 2020

Sponsoring Org.:

USDOE

OSTI Identifier:

1787370

Resource Type:

Publisher's Accepted Manuscript

Journal Name:

Transfusion (Philadelphia)

Additional Journal Information:

Journal Name: Transfusion (Philadelphia) Journal Volume: 60 Journal Issue: 12; Journal ID: ISSN 0041-1132

Publisher:

Wiley-Blackwell

Country of Publication:

United States

Language:

English